(FDMT) 4D Molecular Therapeutics - Ratings and Ratios
Gene Therapy, Biotech Drugs, Retinal Disease, Cystic Fibrosis, Fabry Disease
FDMT EPS (Earnings per Share)
FDMT Revenue
Description: FDMT 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a late-stage biotechnology company focused on developing innovative gene therapies using its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution. The companys lead product candidate, 4D-150, is being developed for the treatment of retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema.
The companys pipeline includes several other promising candidates: 4D-710 for cystic fibrosis, 4D-175 for geographic atrophy, 4D-725 for alpha-1 anti-trypsin deficiency lung disease, and 4D-310 for Fabry disease. These candidates are in various stages of development, from preclinical to Phase 1 clinical trials. 4DMTs collaborations with Astellas Gene Therapies, Arbor Biotechnologies, and uniQure biopharma B.V. demonstrate its potential for growth and innovation in the gene therapy space.
To evaluate the companys performance, we can look at key performance indicators (KPIs) such as revenue growth, research and development (R&D) expenses, and cash reserves. As a biotech company, 4DMTs R&D expenses are likely to be significant, and its cash reserves will be crucial in determining its ability to fund future development. With a market capitalization of $196.42M USD, the companys financials will be closely watched by investors. Additionally, the companys return on equity (RoE) of -33.27% indicates significant investment in its pipeline, which is expected in the biotech industry.
From a trading perspective, its worth noting that FDMTs stock price has been volatile, with a 52-week high of $27.22 and a low of $2.51. The current price of $4.28 is significantly lower than its 52-week high, indicating a potential buying opportunity for investors. However, the lack of revenue and significant R&D expenses mean that investors will need to carefully consider the companys prospects and potential risks.
FDMT Stock Overview
| Market Cap in USD | 302m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-12-11 |
FDMT Stock Ratings
| Growth Rating | -50.5% |
| Fundamental | 25.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -65.3% |
| Analyst Rating | 4.0 of 5 |
FDMT Dividends
Currently no dividends paidFDMT Growth Ratios
| Growth Correlation 3m | 90.7% |
| Growth Correlation 12m | -54.9% |
| Growth Correlation 5y | -64.7% |
| CAGR 5y | -7.78% |
| CAGR/Max DD 3y | -0.08 |
| CAGR/Mean DD 3y | -0.21 |
| Sharpe Ratio 12m | -1.32 |
| Alpha | -68.68 |
| Beta | 0.469 |
| Volatility | 75.05% |
| Current Volume | 465.4k |
| Average Volume 20d | 626.6k |
| Stop Loss | 6.3 (-7.4%) |
| Signal | -0.03 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-196.1m TTM) > 0 and > 6% of Revenue (6% = 1980 TTM) |
| FCFTA -0.29 (>2.0%) and ΔFCFTA -16.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 814.0k% (prev 2637 %; Δ 811.3kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.35 (>3.0%) and CFO -166.4m > Net Income -196.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (55.9m) change vs 12m ago 1.17% (target <= -2.0% for YES) |
| Gross Margin -16.2k% (prev 56.23%; Δ -16.2kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.01% (prev 3.26%; Δ -3.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -17.19
| (A) 0.57 = (Total Current Assets 303.3m - Total Current Liabilities 34.7m) / Total Assets 473.6m |
| (B) -1.43 = Retained Earnings (Balance) -678.8m / Total Assets 473.6m |
| warn (B) unusual magnitude: -1.43 — check mapping/units |
| (C) -0.41 = EBIT TTM -222.2m / Avg Total Assets 546.9m |
| (D) -12.86 = Book Value of Equity -678.5m / Total Liabilities 52.7m |
| Total Rating: -17.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.23
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.06 = 2.50 |
| 5. Debt/Ebitda -0.11 = -2.50 |
| 6. ROIC - WACC -53.00% = -12.50 |
| 7. RoE -40.15% = -2.50 |
| 8. Rev. Trend -34.11% = -1.71 |
| 9. Rev. CAGR -72.06% = -2.50 |
| 10. EPS Trend -22.34% = -0.56 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of FDMT shares?
Over the past week, the price has changed by -2.44%, over one month by -6.34%, over three months by +55.61% and over the past year by -58.74%.
Is 4D Molecular Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FDMT is around 6.23 USD . This means that FDMT is currently overvalued and has a potential downside of -8.38%.
Is FDMT a buy, sell or hold?
- Strong Buy: 5
- Buy: 4
- Hold: 2
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the FDMT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.4 | 347.1% |
| Analysts Target Price | 30.4 | 347.1% |
| ValueRay Target Price | 6.9 | 1.3% |
Last update: 2025-09-05 04:42
FDMT Fundamental Data Overview
CCE Cash And Equivalents = 293.2m USD (Cash And Short Term Investments, last quarter)
P/S = 9156.52
P/B = 0.719
Beta = 2.822
Revenue TTM = 33.0k USD
EBIT TTM = -222.2m USD
EBITDA TTM = -221.8m USD
Long Term Debt = 18.1m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 5.72m USD (from shortTermDebt, last quarter)
Debt = 23.8m USD (Calculated: Short Term 5.72m + Long Term 18.1m)
Net Debt = -54.1m USD (from netDebt column, last quarter)
Enterprise Value = 32.7m USD (302.2m + Debt 23.8m - CCE 293.2m)
Interest Coverage Ratio = unknown (Ebit TTM -222.2m / Interest Expense TTM 0.0)
FCF Yield = -422.7% (FCF TTM -138.4m / Enterprise Value 32.7m)
FCF Margin = -419.3k% (FCF TTM -138.4m / Revenue TTM 33.0k)
Net Margin = -594.4k% (Net Income TTM -196.1m / Revenue TTM 33.0k)
Gross Margin = -16.2k% ((Revenue TTM 33.0k - Cost of Revenue TTM 5.38m) / Revenue TTM)
Tobins Q-Ratio = -0.05 (set to none) (Enterprise Value 32.7m / Book Value Of Equity -678.5m)
Interest Expense / Debt = 5.94% (Interest Expense 1.41m / Debt 23.8m)
Taxrate = 21.0% (US default)
NOPAT = -222.2m (EBIT -222.2m, no tax applied on loss)
Current Ratio = 8.75 (Total Current Assets 303.3m / Total Current Liabilities 34.7m)
Debt / Equity = 0.06 (Debt 23.8m / last Quarter total Stockholder Equity 420.9m)
Debt / EBITDA = -0.11 (Net Debt -54.1m / EBITDA -221.8m)
Debt / FCF = -0.17 (Debt 23.8m / FCF TTM -138.4m)
Total Stockholder Equity = 488.5m (last 4 quarters mean)
RoA = -41.41% (Net Income -196.1m, Total Assets 473.6m )
RoE = -40.15% (Net Income TTM -196.1m / Total Stockholder Equity 488.5m)
RoCE = -43.86% (Ebit -222.2m / (Equity 488.5m + L.T.Debt 18.1m))
RoIC = -45.49% (NOPAT -222.2m / Invested Capital 488.5m)
WACC = 7.52% (E(302.2m)/V(326.0m) * Re(7.74%)) + (D(23.8m)/V(326.0m) * Rd(5.94%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 90.91 | Cagr: 5.09%
Discount Rate = 7.74% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -138.4m)
EPS Correlation: -22.34 | EPS CAGR: 0.0% | SUE: -1.84 | # QB: False
Revenue Correlation: -34.11 | Revenue CAGR: -72.06%
Additional Sources for FDMT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle